Recent quotes:

Pure Omega-3 prescription drug markedly reduces first, repeat and total CV events: New data show 4 gram dose of icosapent ethyl may be new, cost-effective way to prevent CV complications among patients with elevated triglycerides who have heart disease or diabetes -- ScienceDaily

Compared with placebo, icosapent ethyl cut the combined rate of first and subsequent cardiovascular deaths, nonfatal heart attacks or strokes, procedures for coronary artery disease such as stenting, or hospitalizations for unstable angina (the study's primary endpoint) by 30 percent, demonstrating the drug may be more protective than previously reported. Earlier analyses of the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT), which were primarily focused on the first occurrence of a major adverse cardiovascular event, found a 25 percent reduction. This latest analysis aimed to determine the extent to which the drug reduced the total burden of (first and subsequent) cardiovascular events. "In looking at the totality of events -- not just the first ones, but subsequent ones too -- we see that the drug provides even greater reductions in ischemic events. By looking only at first events, we underestimate the true underlying treatment benefit offered," said Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women's Hospital, professor of medicine at Harvard Medical School and the study's lead author. "From a patient's perspective certainly, and from a physician's point of view, icosapent ethyl's impact on total events is what matters most."